Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.
-
- STATUS
- Recruiting
-
- End date
- Dec 24, 2023
-
- participants needed
- 10
-
- sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-nave patients after resection of glioblastoma.
Description
This clinical trail includes two phases: basic treatment phase and immunotherapy phase. In basic treatment phase, patients will receive concomitant radiation and TMZ-chemotherapy. In immunotherapy phase, besides maintenance chemotherapy with TMZ, Fusion cells will be administered with IL-12 to enhance the immunity of patients.
Details
| Condition | Neuroectodermal Tumor, Neurectoderma, biological response modifier, Cancer, Cancer/Tumors, Neoplasms, Cancer (Pediatric), Ewing's Family Tumors, Cancer, Glioma, Gliomas, Glioblastoma Multiforme, Glioblastoma Multiforme, Vaccine Therapy, Gliomatosis cerebri, Vaccines, Vaccines, Neoplasms, Nerve Tissue, Germ cell tumor, Germ Cell Tumors, Cancer/Tumors, Ewing's Family Tumors, Cancer (Pediatric), Neurectoderma, Gliomas, Neoplasms, Germ Cell Tumors, Therapeutic Vaccine, glioblastoma, glial tumor |
|---|---|
| Treatment | Temozolomide, Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12 |
| Clinical Study Identifier | NCT04388033 |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Last Modified on | 24 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer